SCHEMBL794180

SCHEMBL794180

CC([CH]Cc1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.46
TRPA1 O75762 3/20 0.46
SIGMAR1 Q99720 3/20 0.41
TAAR1 Q96RJ0 7/20 0.40
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MAOA P21397 1/20 0.40
CYP2A6 P11509 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
MAPK1 P28482 1/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
HTR1A P08908 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27554181 0.82 MAOA (0.44) MAOBSIGMAR1TAAR1SLC6A2SLC6A4
SCHEMBL1289345 0.79 MAOB (0.52) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL10348037 0.79 MAOB (0.54) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL3624305 0.79 TRPA1 (0.43) TRPA1SIGMAR1TAAR1SLC6A2SLC6A4
Phenylacetaldehyde SCHEMBL10627457 0.78 TAAR1 (0.42) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL8710872 0.77 MAOB (0.50) MAOBSIGMAR1TAAR1SLC6A2SLC6A4
SCHEMBL4155331 0.76 MAOB (0.48) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL8174260 0.76 MAOB (0.48) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL3295095 0.76 MAOB (0.48) MAOBTRPA1SIGMAR1TAAR1SLC6A2
SCHEMBL9205893 0.76 TAAR1 (0.52) TRPA1TAAR1ADRA2CHTR2AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103665018-B Silane compound and preparation method thereof 中国石油化工股份有限公司 2017-02-15 CN claimed
WO-2001052868-A9 COMBINATIONS FOR TREATING NEOPLASMS YU BAOFA (US) 2003-01-16 WO claimed
US-5127935-A Halogen, phenyl and heterocycle substituents, agricultural use NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-07-07 US claimed
EP-2139835-B1 METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS BASF SE (DE) 2017-05-10 EP disclosed
EP-2352719-B1 METHOD FOR PRODUCING N,N-SUBSTITUTED-3-AMINOPROPAN-1-OLS BASF SE (DE) 2016-06-08 EP disclosed
EP-3023418-A1 METHOD FOR MANUFACTURING CYCLIC CARBONATE National Institute of Advanced Industrial Science and Technology (JP) 2016-05-25 EP disclosed
EP-2616429-B1 METHOD FOR PRODUCING AROMATIC AMINES BASF SE (DE) 2015-08-05 EP disclosed
US-20130281680-A1 PROCESS FOR PRODUCING COELENTERAMIDE OR AN ANALOG THEREOF JNC CORP (JP) 2013-10-24 US disclosed
EP-2616429-A1 METHOD FOR PRODUCING AROMATIC AMINES BASF SE (DE) 2013-07-24 EP disclosed
EP-2279164-B1 METHOD FOR PRODUCING N,N-SUBSTITUTED-1,3-PROPANDIAMINES BASF SE (DE) 2012-03-28 EP disclosed
WO-2012034933-A1 METHOD FOR PRODUCING AROMATIC AMINES BASF SE (DE) 2012-03-22 WO disclosed
WO-2006040096-A1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2006-04-20 WO disclosed
EP-1537071-B1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 2-AMINO-,2-CHLORO-,2-HYDROXY- OR 2-ALKOXY-1-ALCOHOLS BASF AG (DE) 2006-04-05 EP disclosed
WO-2005077870-A1 HYDROGENATION METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOLS OR CARBOXYLIC ACIDS BASF AKTIENGESELLSCHAFT (DE) 2005-08-25 WO disclosed
WO-2005077871-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOLS OR CARBOXYLIC ACIDS BASF AKTIENGESELLSCHAFT (DE) 2005-08-25 WO disclosed
EP-1537071-A1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 2-AMINO-,2-CHLORO-,2-HYDROXY OR 2-ALKOXY-1-ALCOHOLS BASF AKTIENGESELLSCHAFT (DE) 2005-06-08 EP disclosed
WO-2004022522-A1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 2-AMINO-,2-CHLORO-,2-HYDROXY OR 2-ALKOXY-1-ALCOHOLS BASF AKTIENGESELLSCHAFT (DE) 2004-03-18 WO disclosed
US-6511997-B1 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease TEIKOKU HORMONE MFG. CO., LTD. (JP) 2003-01-28 US disclosed
WO-2001052868-A9 COMBINATIONS FOR TREATING NEOPLASMS YU BAOFA (US) 2003-01-16 WO disclosed
EP-0596125-A1 CONDENSED THIOPHENE COMPOUND AND PHARMACEUTICAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281680-A1 PROCESS FOR PRODUCING COELENTERAMIDE OR AN ANALOG THEREOF HNMT, DIMT1, SI MAOB 463/4885TRPA1 2660/4885SIGMAR1 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.